Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 20.9% in February

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the target of a significant increase in short interest in February. As of February 13th, there was short interest totaling 82,140 shares, an increase of 20.9% from the January 29th total of 67,935 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average trading volume of 51,786 shares, the short-interest ratio is presently 1.6 days. Based on an average trading volume of 51,786 shares, the short-interest ratio is presently 1.6 days. Currently, 1.7% of the company’s stock are short sold.

Evaxion A/S Price Performance

Shares of NASDAQ EVAX opened at $3.12 on Wednesday. The business has a 50-day moving average of $4.01 and a two-hundred day moving average of $4.62. The company has a market capitalization of $26.02 million, a price-to-earnings ratio of -8.00 and a beta of 0.28. Evaxion A/S has a 1 year low of $1.20 and a 1 year high of $12.15.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on EVAX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Maxim Group began coverage on Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Evaxion A/S currently has an average rating of “Moderate Buy” and an average target price of $11.75.

Institutional Trading of Evaxion A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EVAX. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Evaxion A/S during the 4th quarter worth approximately $38,000. Wesbanco Bank Inc. acquired a new stake in Evaxion A/S during the 4th quarter worth $48,000. Finally, SmartHarvest Portfolios LLC purchased a new stake in Evaxion A/S in the fourth quarter valued at $72,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.